Atlas Trials

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

Clinical trial NCT02326272 · COMPLETED

Trial details

NCT number
NCT02326272
Sponsor
UCB Biopharma S.P.R.L.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
PsoriasisPlaque Psoriasis
Start date
2014-12-15
Primary completion
2016-01-05
Enrollment
227

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.